CLLS logo

Cellectis SA (CLLS)

Profile

Full Name

Cellectis S.A.

Ticker Symbol

CLLS

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

France

IPO

March 24, 2015

Indexes

Not included

Website

http://www.cellectis.com

Employees

216

Key Details

Price

$1.45(+1.40%)

Market cap

$145.14M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$41.51M(+5397.48% YoY)

Annual EPS

-$0.41(+76.84% YoY)

PE ratio

-

Next earnings date

May 28, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.45
CLLS price is $1.45

30-Day Relative Volume

0.06
CLLS 30-day relative volume is 0.06

Price Performance

Price Most recent change

+1.4%
CLLS price was up +1.4% on Apr 17, 2025

Price YTD change

-19.44%
CLLS price is down -19.44% since January 1st

Price 1-year change

-41.06%
CLLS price is down -41.06% year-on-year

Price 3-year change

-64.89%
CLLS price is down -64.89% over the past 3 years

Price Range

Price All-time high

$50.00
CLLS price is currently -97.10% below its historical high of $50.00

Price 3-year low

$0.96
CLLS price is currently +50.57% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$145.14M
CLLS market capitalization is $145.14 million

Market cap 3-year change

-22.75%
CLLS market capitalization is down -22.75% over the past 3 years

Market cap All-time high

$1.48B
CLLS market capitalization is currently -90.18% below its historical high of $1.48 billion

Market cap sector rank

52.84%
CLLS market capitalization is higher than 52.84% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+39.11%
CLLS shares outstanding is up +39.11% year-on-year

Shares Outstanding 3-Year Change

+120.03%
CLLS shares outstanding is up +120.03% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.68
CLLS beta is 0.68

200-day SMA

$1.81
CLLS price is currently -19.98% below its 200-day simple moving average

50-day SMA

$1.35
CLLS price is currently +7.26% above its 50-day simple moving average

RSI

60.28
CLLS 14-day relative strength index is 60.28

Volume

0.06
CLLS 30-day relative volume is 0.06

ATR

$0.10
CLLS average true range is $0.10

10-day Historical Volatility

95.20%
CLLS 10-day historical volatility is 95.20%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$41.51M
CLLS annual revenue is $41.51 million

Revenue Analysts estimate

$50.66M
CLLS annual revenue is currently -18.07% lower than the consensus analysts' forecast

Revenue 1-year change

+5397.48%
CLLS annual revenue is up +5397.48% year-on-year

Revenue Sector rank

44.62%
CLLS annual revenue is higher than 44.62% of companies in Healthcare sector

EPS

EPS

-$0.41
CLLS annual earnings per share is -$0.41

EPS Analysts estimate

-$0.46
CLLS annual earnings per share is currently -10.87% lower than the consensus analysts' forecast

EPS 1-year change

+76.84%
CLLS annual earnings per share is up +76.84% year-on-year

EPS Sector rank

70.92%
CLLS annual earnings per share is higher than 70.92% of companies in Healthcare sector

Profit

Gross profit

$41.51M
CLLS annual gross profit is $41.51 million

Gross margin

-
CLLS annual gross profit margin value is unknown

Operating profit

-$59.55M
CLLS annual operating income is -$59.55 million

Operating margin

-143.48%
CLLS annual operating profit margin is -143.48%

Net income

-$36.76M
CLLS annual net profit is -$36.76 million

Net margin

-88.57%
CLLS annual net profit margin is -88.57%

Expenses

Total expenses

$101.06M
CLLS annual total expenses is $101.06 million

Operating expenses

$101.06M
CLLS annual total operating expenses is $101.06 million

Cost of goods sold

-
CLLS annual cost of goods sold value is unknown

Selling, general & administrative expenses

$17.60M
CLLS annual SGA is $17.60 million

Depreciation and amortization

$19.85M
CLLS annual depreciation & amortization is $19.85 million

Interest expense

$7.45M
CLLS annual interest expense is $7.45 million

Income tax

$0.00
CLLS annual income tax is $0.00

EBIT & EBITDA

EBIT

-$29.31M
CLLS annual earnings before interest & taxes is -$29.31 million

EBITDA

-$9.46M
CLLS annual EBITDA is -$9.46 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$383.54M
CLLS annual total assets is $383.54 million

Non current assets

$96.48M
CLLS annual long term assets is $96.48 million

Current assets

$287.07M
CLLS annual total current assets is $287.07 million

Cash and cash equivalents

$143.25M
CLLS annual cash & cash equivalents is $143.25 million

Accounts receivable

$6.71M
CLLS annual accounts receivable is $6.71 million

Inventory

-
CLLS annual inventory value is unknown

Liabilities

Total liabilities

$252.51M
CLLS annual total liabilities is $252.51 million

Long term liabilities

$86.24M
CLLS annual total long term liabilities is $86.24 million

Current liabilities

$166.27M
CLLS annual total current liabilities is $166.27 million

Accounts payable

$18.66M
CLLS annual accounts payable is $18.66 million

Debt

Total debt

$91.46M
CLLS annual total debt is $91.46 million

Total debt 1-year change

+7.53%
CLLS annual total debt is up +7.53% year-on-year

Long term debt

$78.23M
CLLS annual long term debt is $78.23 million

Short term debt

$13.23M
CLLS annual short term debt is $13.23 million

Equity & Capital

Shareholders equity

$131.03M
CLLS annual stockholders equity is $131.03 million

Book value

$131.03M
CLLS annual book value is $131.03 million

Retained earnings

-$329.61M
CLLS annual retained earnings is -$329.61 million

Working capital

$120.80M
CLLS annual working capital is $120.80 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$22.99M
CLLS annual cash flow from operations is $22.99 million

Cash from operations 1-year change

+192.9%
CLLS annual cash flow from operations is up +192.9% year-on-year

Cash from investing

-$102.81M
CLLS annual cash flow from investing activities is -$102.81 million

Cash from investing 1-year change

-562.85%
CLLS annual cash flow from investing activities is down -562.85% year-on-year

Cash from financing

$89.11M
CLLS annual cash flow from financing activities is $89.11 million

Cash from financing 1-year change

+7.54%
CLLS annual cash flow from financing activities is up +7.54% year-on-year

CAPEX

CAPEX

$3.84M
CLLS annual capital expenditures is $3.84 million

CAPEX 1-year change

+258.15%
CLLS annual capital expenditures is up +258.15% year-on-year

Free Cash Flow

Free cash flow

$19.15M
CLLS annual free cash flow is $19.15 million

Free cash flow 1-year change

+174.15%
CLLS annual free cash flow is up +174.15% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
CLLS annual gross profit margin value is unknown

Operating margin

-143.48%
CLLS annual operating profit margin is -143.48%

Net margin

-88.57%
CLLS annual net profit margin is -88.57%

ROA & ROE

ROA

-10.24%
CLLS annual return on assets is -10.24%

ROE

-34.08%
CLLS annual return on equity is -34.08%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
CLLS price to earnings ratio value is unknown

PE ratio Sector rank

-
CLLS price to earnings ratio is unknown

PB Ratio

PB ratio

1.11
CLLS price to book ratio is 1.11

PB ratio Sector rank

46.5%
CLLS price to book ratio is higher than 46.5% of companies in Healthcare sector

PS Ratio

PS ratio

3.50
CLLS price to sales ratio is 3.50

PS ratio Sector rank

57.38%
CLLS price to sales ratio is higher than 57.38% of companies in Healthcare sector

Enterprise value

Enterprise value

$93.35M
CLLS enterprise value is $93.35 million

Enterprise value Sector rank

49.09%
CLLS enterprise value is higher than 49.09% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-9.87
CLLS EV/EBITDA is -9.87

EV/EBITDA Sector rank

11.23%
CLLS EV/EBITDA is higher than 11.23% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.73
CLLS annual current ratio is 1.73

Quick ratio

-
CLLS annual quick ratio value is unknown

Leverage

Debt to equity

0.37
CLLS annual debt to equity ratio is 0.37

Interest coverage ratio

-3.93
CLLS annual interest coverage ratio is -3.93

Risk & Stability

Piotroski F-Score

-
CLLS piotroski f-score value is unknown

Altman Z-Score

-0.62
CLLS altman z-score is -0.62

Analyst ratings

Recent major analysts updates

Nov 5, 24 Barclays
Overweight
Jun 12, 24 Oppenheimer
Outperform
May 31, 24 JMP Securities
Market Outperform
Nov 1, 23 JMP Securities
Market Outperform
Aug 8, 23 Oppenheimer
Outperform
Aug 7, 23 JMP Securities
Market Outperform
Apr 5, 23 Citigroup
Buy
Mar 13, 23 Oppenheimer
Outperform
Mar 13, 23 JMP Securities
Market Outperform
Jan 19, 23 JMP Securities
Market Outperform

Institutional Ownership

Similar stocks

DERM logo
Journey Medical (DERM)
MOLN logo
Molecular Partners AG (MOLN)
CATX logo
Perspective Therapeutics (CATX)
PROF logo
Profound Medical (PROF)
TARA logo
Protara Therapeutics (TARA)
ZJYL logo
Jin Medical International (ZJYL)
SLN logo
Silence Therapeutics (SLN)
PBYI logo
Puma Biotechnology (PBYI)
FDMT logo
4D Molecular Therapeutics (FDMT)
  • What is the ticker symbol for Cellectis SA?
  • Does Cellectis SA pay dividends?
  • What sector is Cellectis SA in?
  • What industry is Cellectis SA in?
  • What country is Cellectis SA based in?
  • When did Cellectis SA go public?
  • Is Cellectis SA in the S&P 500?
  • Is Cellectis SA in the NASDAQ 100?
  • Is Cellectis SA in the Dow Jones?
  • When was Cellectis SA's last earnings report?
  • When does Cellectis SA report earnings?
  • Should I buy Cellectis SA stock now?

What is the ticker symbol for Cellectis SA?

The ticker symbol for Cellectis SA is NASDAQ:CLLS

Does Cellectis SA pay dividends?

No, Cellectis SA does not pay dividends

What sector is Cellectis SA in?

Cellectis SA is in the Healthcare sector

What industry is Cellectis SA in?

Cellectis SA is in the Biotechnology industry

What country is Cellectis SA based in?

Cellectis SA is headquartered in France

When did Cellectis SA go public?

Cellectis SA's initial public offering (IPO) was on March 24, 2015

Is Cellectis SA in the S&P 500?

No, Cellectis SA is not included in the S&P 500 index

Is Cellectis SA in the NASDAQ 100?

No, Cellectis SA is not included in the NASDAQ 100 index

Is Cellectis SA in the Dow Jones?

No, Cellectis SA is not included in the Dow Jones index

When was Cellectis SA's last earnings report?

Cellectis SA's most recent earnings report was on Mar 13, 2025

When does Cellectis SA report earnings?

The next expected earnings date for Cellectis SA is May 28, 2025

Should I buy Cellectis SA stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page